Peter Berger, MD, FACC, FAHA
Associate Chief Research Officer
LOCATION
Center for Clinical Studies
100 North Academy Avenue
Danville, PA 17822
Phone: 570-214-5057
Fax: 570-214-9451
pbberger@geisinger.edu
EDUCATION
MD, New York University School of Medicine, 1979-1983
Internal Medicine Residency, Boston City Hospital, 1983-1986
Cardiology Fellowship, Boston University Medical School, 1986-1988
Interventional Fellowship, Boston University Medical School, 1988-1990
RESEARCH FOCUS
Clinical Trials, Outcomes
EXPERTISE
Cardiovascular Disease, Revascularization strategies in acute and chronic ischemic syndromes
RESEARCH INTERESTS
Peter B. Berger, M.D. is currently the Associate Chief Research Officer at Geisinger Clinic and Director of the Center for Clinical Studies, and is responsible for clinical research throughout the 3 hospitals and 40 clinics in the Geisinger Health System. He is also an interventional cardiologist at Geisinger. Prior to joining Geisinger, he was a Professor of Medicine and the Director of Interventional Cardiology at the Duke University Medical Center. He was also Co-Director of Cardiovascular Device Research at the Duke Clinical Research Institute. Before that, Dr. Berger was a Professor of Medicine in the Division of Cardiology at the Mayo Clinic College of Medicine for 14 years. Dr. Berger has over 18 years of experience performing clinical research in investigator-initiated, federally-funded, and industry-sponsored studies. He has served as a member of the steering committees of many of the large phase 3 cardiovascular trials that have shaped clinical practice in recent years. His current research efforts focus on revascularization strategies in acute and chronic ischemia and novel antiplatelet and antithrombin therapies. He is also heavily involved with biobanking at Geisinger in many different disciplines.
RECENT PUBLICATIONS
Shaw LJ, Berman DS, Maron DJ, Mancini GBJ, Hayes SW, Hartigan PM, Weintraub WS, O'Rourke RA, Dada M, Spertus JA, Chaitman BR, Friedman J, Slomka P, Heller GV, Germano G, Gosselin G, Berger P, Kostuk WJ, Schwartz RG, Knudtson M, Veledar E, Bates ER, McCallister B, Teo KK, Boden WE, for the COURAGE Investigators. (2008, March). Optimal Medical Therapy With or Without Percutaneous Coronary Intervention to Reduce Ischemic Burden: Results From the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial Nuclear Substudy. Circulation, 117(10):1283-91.
Kastrati A, Neumann F-J, Mehilli J, Byrne RA, Iijima AA, Schultz S, Blankenship JC, Pache J, Minners J, Seyfarth M, Graf I, Skelding KA, Dirschinger J, Richardt G, Berger PB, Schömig A, for the ISAR-REACT3 Trial Investigators. (2008, August). Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med, 359(7):688-96.
Jeremias A, Kleiman NS, Nassef D, Hsieh W-H, Pencina MJ, Marish K, Parikh MA, Cutlip DE, Waksman R, Goldberg S, Berger PB, Cohen DJ. (2008, August). Prevalence and prognostic significance of pre-procedure cardiac troponin elevation among patients with stable coronary artery disease undergoing percutaneous coronary intervention: Results from the EVENT Registry. Circulation, 118(6):632-8.
Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ, for the CHARISMA Investigators. (2006). A randomized trial evaluating dual anti-platelet therapy with clopidogrel and aspirin, compared with aspirin alone, in patients at risk for atherothrombotic events (the CHARISMA trial*). New Engl J Med, 354:1706-1717.
Steinhubl SR, Berger PB, Mann JT, Fry ETA, DeLago A, Wilmer C, Topol EJ for the CREDO Investigators. (2002, November). Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. A randomized controlled trial. JAMA, 288(19):2411-2420.